Learn how our scientists are using this innovative immunotherapy — a type of living drug — to offer patients hope.
Your own body is one of your best defenses against cancer. Memorial Sloan Kettering scientists are learning how to harness the power of the body’s immune system to fight cancer, an approach called immunotherapy.
Racing to the front of the pack is a type of immunotherapy called chimeric antigen receptor (CAR) T cell therapy. In this approach, immune cells are removed from a patient, armed with new proteins that allow them to recognize cancer, and given back to the patient in large numbers. These cells persist in the body, becoming “living drugs.”
MSK scientists pioneered this approach, and they are working hard to improve and expand it. See how this treatment works.
Hear from a patient who has benefited from CAR T.
- MSK is currently running CAR T-focused clinical trials for several different types of cancer.
- MSK scientists pioneered CAR T cell therapy for cancer.
- More than 80 percent of acute leukemia patients treated with CD19-directed CARs at MSK have seen their cancer regress.
- MSK scientists were the first to show that CD19 was a good target for CAR T cells.
- MSK scientists are exploring ways to make CAR T cell therapy safer, with fewer side effects.
- Call 1-888-MSK-CART to learn more about treatment for certain blood cancers.
Expert Patient Care
Our doctors and nurses have unparalleled expertise in caring for patients who are receiving this treatment. There are risks associated with receiving CAR T cells, but our clinicians — including members of the Cellular Therapeutics Center and the Bone Marrow Transplant Service — have vast experience in managing side effects, which are usually reversible.
CAR T cell therapy has proven very effective at treating acute lymphoblastic leukemia (ALL) in both children and adults. This type of blood cancer is usually treated successfully with chemotherapy, but in some cases conventional approaches do not work. That’s when CAR T cell therapy can be a patient’s best option.
When chemotherapy couldn’t get Esmeralda Pineda’s pediatric leukemia under control, doctors at Memorial Sloan Kettering turned to immunotherapy. The successful treatment wiped out all signs of her disease, and one year later, she’s still cancer free. Read Ezzy’s story
When avid golfer Karen Koehler was sidelined by cancer, CAR T immunotherapy got her back in full swing. Read Karen’s story
CAR T cells are also being explored as a treatment for several other types of cancer, including lymphoma, lung cancer, breast cancer, mesothelioma, ovarian cancer, and multiple myeloma. To search for an open CAR T trial at MSK, visit our clinical trial database.
Find out more about receiving CAR T cell treatment at Memorial Sloan Kettering.
Medical oncologist Melody Smith treats children and young adults with blood cancers.
Isabelle Rivière directs the Cell Therapy and Cell Engineering Facility at MSK.
Roisin O'Cearbhaill is a medical oncologist who treats patients with gynecologic cancers.
Ezzy Pineda received CAR T therapy in 2016 and is now cancer free.
Putting CARs on the Road
In the early 1990s, the techniques to introduce genes into cells were just being developed. Dr. Sadelain wanted to use the new techniques to engineer T cells, giving them souped-up capabilities.
“At the time it sounded very pipe dream,” one of Dr. Sadelain’s doctoral thesis advisers told the New York Times. But Dr. Sadelain “believed in his approach and he pursued it relentlessly.”
A decade later, in 2002, Dr. Sadelain and his MSK colleagues, including Isabelle Rivière and Renier Brentjens, published a now seminal article showing that T cells engineered with a chimeric antigen receptor could kill tumor cells and persist in the body. They were also the first ones to show that targeting a marker called CD19, found on the surface of blood cells, was a good way to kill leukemia and lymphoma.
The FDA granted CD19 CAR T cells a Breakthrough Therapy designation for relapsed or refractory ALL in 2014. “CAR T cells are making history, beyond any doubt,” Dr. Sadelain says.
Manufacturing Living Drugs
Using cells as drugs requires a sterile facility that can manufacture these sophisticated cellular products under strict controls. MSK has an entire core facility devoted to this vital task.
Administering investigational CAR T cells safely and effectively is the job of members of MSK’s Cellular Therapeutics Center, led by physician-scientist Renier Brentjens. From designing clinical trials to working with other centers to establish CAR T programs, the members of this center are leaders in the clinical application of CARs.
The scientists and clinicians associated with the CAR T program at MSK work together to provide seamless care for patients. New models of CAR T cells are designed, built, and tested right here at MSK.
CARs in the News
The following is a selection of media articles and videos about CAR T therapy:
- Gene Therapy Will Transform Medicine. BBC Two. June 19, 2017.
- Immunotherapy: The next frontier in cancer treatment. CBS News. March 12, 2017.
- CRISPR Turbocharges CAR T Cells, Boosts Cancer Immunotherapy. Genetic Engineering and Biotechnology News. February 23, 2017.
- Setting the Body’s ‘Serial Killers’ Loose on Cancer. New York Times. August 1, 2016.
- Biotech’s Coming Cancer Cure. MIT Technology Review. June 18, 2015.
- The CAR T-Cell Race. The Scientist. April 1, 2015
For media inquires, please visit our pressroom.